# NADMED

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nadmed

- Industry: Medical Devices & Equipment
- Headquarters: Helsinki, Finland
- Website: www.nadmed.com/
- Total disclosed funding: $3.9M
- Latest round: Series A (Aug 22, 2024)
- Investors on record: 3

## About

Based in Helsinki, Finland, and founded in 2022 by co-founders Jari Narhi (CEO), Jana Buzkova, Liliya Euro, and Anu Wartiovaara MD, NADMED Ltd operates as a provider of advanced measurement kits for NAD and glutathione to clinical laboratories and research facilities, supporting accurate analysis and research. In August 2024, NADMED Ltd raised an undisclosed amount of grant funding from Business Finland Venture Capital.

The company provides a wide range of laboratory services and measurement products, such as CE-marked assay kits for NAD+ and NADH from whole blood, tissue, or cells, NADP+ and NADPH assay kits, and NAD purity tests. Additionally, the firm also provides laboratory services for NAD and glutathione measurements in human and animal samples.

## Funding rounds

- Series A, Aug 22, 2024, $3.9M — Helsinki University Funds, Voima Ventures, Nordic Science Investments

## Investors

- Helsinki University Funds — Series A
- Voima Ventures (https://capitalatlas.ai/funds/voima-ventures) — Series A
- Nordic Science Investments (https://capitalatlas.ai/funds/nordic-science-investments) — Series A